Scientific Publications

Innovative scientific research aimed at developing non-invasive diagnostics and broad-spectrum therapeutics in the fight against cancer

Diagnostics

CyPath® Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk.

Therapeutics

Through our subsidiary, OncoSelect® Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics.

Peer-Reviewed Papers & Conference Presentations

Scientific Publications

Scientific Papers

Sputum analysis by flow cytometry; an effective platform to analyze the lung environment

"Sputum analysis by flow cytometry; an effective platform to analyze the lung environment" PLoS ONE – August 17, 2022   Authors Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al.   Abstract Low-dose computed tomography (LDCT) is the standard of care for lung cancer screening in the United States (US). LDCT has a sensitivity of 93.8% but its specificity of 73.4% leads to potentially harmful follow-up procedures in patients without lung cancer. Thus, there is a need for additional assays with high accuracy that can be used as an adjunct to LDCT to diagnose lung cancer. Sputum is a biological fluid that can be obtained non-invasively and can be dissociated to release its cellular...
Read More

Quality-Controlled Sputum Analysis by Flow Cytometry

"Quality-Controlled Sputum Analysis by Flow Cytometry" Journal of Visualized Experiments (JoVE) – August 9, 2021   Authors Marcia Grayson, Shao-Chiang Lai, Lydia H. Bederka, Patricia Araujo, Jamila Sanchez, Xavier T. Reveles, Vivienne I. Rebel, Jennifer Rebeles   Abstract Sputum, widely used to study the cellular content and other microenvironmental...

Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors

“Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 – 25, 2021   Authors David J. Elzi, William E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and Vivienne I....

Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin mediated endocytosis

“Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin-mediated endocytosis, Poster Presentation" American Society of Cell Biology’s Cell Bio Virtual 2020; Cancer Therapy: Defining Therapeutic Targets and New Therapeutics, December 2-16, 2020   Authors D. J. Elzi, W. E. Bauta, J. R. Sanchez,...

Sputum-Derived Cellular Profiles Produced by Flow Cytometric Analysis

"Sputum-Derived Cellular Profiles Produced by Flow Cytometric Analysis, Poster" International Society for Advancement of Cytometry CYTO 2020, August 4-5, 2020   Authors Lydia H. Bederka, Shao-Chiang Lai, Jennifer Rebeles, Marcia H. Grayson, Xavier T. Reveles, and Vivienne I. Rebel   Abstract Sputum consists of a complex mixture of mucus...

Internal Validation Research Trial

Internal Validation Research Trial February 1, 2015 27 sputum samples: 15 lung cancer sputum samples and 12 sputum samples from patients without lung cancer, December, 2008 AuthorsT. Bauer II, MD, Helen F. Graham Cancer Center; D. Merrick, MD, Denver VA Medical Center; T. C. Kennedy, MD, University of Colorado...

Research at Los Alamos National Laboratory and St Mary’s Hospital

Research at Los Alamos National Laboratory and St Mary’s Hospital January 15, 2015 St. Mary’s Hospital and the Isotope and Nuclear Chemistry Division of the Medical Radioisotopes Research Program at Los Alamos National Laboratory conducted preliminary studies from 1988 to 1992 researching porphyrins that led to more specific research...
Precision Pathology Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ